Eli Lilly and Company announced today that Leigh Ann Pusey will be joining Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017.
She will be a member of Lilly’s executive committee reporting directly to president and chief executive officer, David A. Ricks.
Pusey currently serves as president and CEO of the American Insurance Association (AIA), an insurance industry trade association representing more than 300 insurers that provide property and casualty insurance in the United States. She joined AIA in December 1996 and was promoted to president and CEO in February 2009. Pusey is consistently recognized by The Hill as one of the top lobbyists in Washington, D.C. and in 2012 she was named by National Journal as one of the 25 “Most Influential Women in Washington.”
“Leigh Ann brings a wealth of public affairs leadership experience to Lilly and at a particularly important time for our industry,” said Ricks. “Her ability to convene conversations and drive proactive policy solutions will be critical in our efforts to promote and sustain medical innovation so patients and the health care system benefit from a new era of medicine.”
Pusey serves in various capacities for a number of organizations, including as a member of the U.S. Chamber of Commerce’s Committee of 100, and board member of the Insurance Institute for Highway Safety. Prior to joining AIA, Pusey had been the deputy assistant to President George H.W. Bush for the White House Office of Public Liaison and deputy director of communications for the Republican National Committee. Pusey is a graduate of Samford University in Birmingham, Alabama. She currently resides in Alexandria, Virginia, with her husband and their two children.
Source: Eli Lilly and Company
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.
Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.
Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.
